


Remarks

Claims 1-17 have been deleted. New claims 18-29 have been added. New claims 18-29 have been submitted to cover only the subject matter falling within the scope of Group V of the restriction requirement made final in the Office Action of June 26, 2001 in great-grandparent application USNN 09/744,414. Applicants respectfully submit that since the above new claims 18-29 correspond to the Group V restriction requirement made by the Examiner, entry of the amendments submitted herewith introduces no new matter to the application.

Examination of claims 18-29 is respectfully requested and allowance of said claims is kindly solicited. An abstract of the application is attached.

Respectfully submitted,



John A. Cleveland, Jr., Ph.D.  
Attorney for Applicants  
Registration No. 50,697  
Phone: 317-276-0307

Eli Lilly and Company  
Patent Division/JAC  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

Feb 6, 2004

ABSTRACT

The present invention relates to the potentiation of glutamate receptor function using certain sulphonamide derivatives. It also relates to novel sulphonamide derivatives, to processes for their preparation and to pharmaceutical compositions containing them.